Oral Mucositis Therapeutics Market Significantly Expand over 2021

The oral mucositis therapeutics market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. 

Logo

Albany, NY -- (SBWire) -- 05/09/2018 --Oral mucositis (OM) is the inflammation of oral mucosa and is manifested by pain and erythema or ulcerations. This condition is generally seen as a complication due to side effects of chemotherapy and radiotherapy in cancer patients. The systemic effects of cytotoxic chemotherapy agents and radiation effects on oral mucosa led to oral mucositis. The National Institutes of Health estimates that more than 400,000 patients in the U.S. are diagnosed with oral mucositis annually. Since the prevalence of cancer patients is on rise across the globe, the market for OM therapeutics is also expanding. In addition, the pain emanated from oral mucositis and the resultant need to cure the condition at the earliest is the foremost driver for the growth of this market.

Request Report for Table of Contents @ https://www.persistencemarketresearch.com/toc/5585

The oral mucositis therapeutics market includes several kinds of drug formulations and treatments such as cryotherapy, growth factors, antioxidants, anti-inflammatory agents, low-level laser therapy (LLLT), mouthwashes, barriers and coating agents. On the basis of geography, the global oral mucositis therapeutics market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. North America is the largest market for OM therapeutics, closely followed by the European region.

The currently marketed major preparations for oral mucositis are Gelclair, Caphosol and Kepivance. Recently, the FDA granted "Fast Track" Designation for SGX942 (Soligenix, Inc.) for the treatment of oral mucositis in patients with head and neck cancer. This drug along with MuGard (tasteless viscous mouth rinse) and pipeline candidate drug nepidermin (Daewoong Pharmaceutical Co.) are expected to further drive the oral mucositis therapeutics market. The major restraint for the development of this market is that most of the drugs are not to be ingested and therefore restricts their usage for esophageal ulcers.

Request to View Sample of Research Report @ https://www.persistencemarketresearch.com/samples/5585

Some of the key players in the global oral mucositis therapeutics market include Access Pharmaceuticals, Inc., EKR Therapeutics, Inc., EUSA Pharma Inc., Swedish Orphan Biovitrum Ltd., Soligenix, Inc., Daewoong Pharmaceutical Co., Eisai Inc., and BioAlliance Pharma SA.

Media Relations Contact

Rahul Singh
Marketing Head
Persistence Market Research
800-961-0353
https://www.persistencemarketresearch.com/

View this press release online at: http://rwire.com/973077